Kimberly Blackwell - 01 Feb 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Executive Officer, Director
Signature: By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Issuer symbol: ZNTL
Transactions as of: 01 Feb 2024
Net transactions value: -$241,457
Form type: 4
Filing time: 05 Feb 2024, 19:11:29 UTC
Previous filing: 13 Nov 2023
Next filing: 13 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+250,000	+98%	$0.000000	504,800	01 Feb 2024	Direct	F1
transaction	ZNTL	Common Stock	Tax liability	$241,457	-20,655	-4.1%	$11.69	484,145	01 Feb 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+250,000		$0.000000	250,000	01 Feb 2024	Common Stock	250,000	$11.69	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2	Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person.
F3	The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.